Simpson Thacher Represents Underwriters in HK$416 Million (US$53.3 Million) Hong Kong IPO and Regulation S Offering by Fusen Pharmaceutical
07.20.18
This is only gets display when printing
The Firm represented the underwriters in the initial public offering and Regulation S offering by Fusen Pharmaceutical Company Limited (“Fusen Pharmaceutical”). Fusen Pharmaceutical offered an aggregate of 200,000,000 Shares (prior to the exercise of the overallotment option), which raised HK$416 Million (US$53.3 Million) in gross proceeds. The shares of Fusen Pharmaceutical are listed on the Hong Kong Stock Exchange. China Securities (International) Corporate Finance Company Limited acted as the sole sponsor. China Securities (International) Corporate Finance Company Limited, ABCI Capital Limited and Bluemount Securities Limited acted as joint global coordinators.
Fusen Pharmaceutical is a leading cold medicine manufacturer based in Henan, China. Its core products are Shuanghuanlian-based cold medicines.
The Simpson Thacher team for the transaction included Chris Wong, Howie Farn and Margaret Li (Corporate).